NEULANDLAB

Neuland Laboratories Share Price

₹15,590.25 +923.9 (6.3%)

17 Nov, 2024 06:54

SIP TrendupStart SIP in NEULANDLAB

Start SIP

Performance

  • Low
  • ₹14,103
  • High
  • ₹16,162
  • 52 Week Low
  • ₹4,926
  • 52 Week High
  • ₹16,561
  • Open Price₹14,610
  • Previous Close₹14,666
  • Volume83,583

Investment Returns

  • Over 1 Month -0.34%
  • Over 3 Month + 34.79%
  • Over 6 Month + 149.83%
  • Over 1 Year + 194.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 71.5
  • PEG Ratio
  • 14.2
  • Market Cap Cr
  • 20,002
  • P/B Ratio
  • 15.7
  • Average True Range
  • 1126.86
  • EPS
  • 205.86
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 385.46
  • RSI
  • 60.07
  • MFI
  • 53.07

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹15,590.25
+ 923.9 (6.3%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹14,326.25
  • 50 Day
  • ₹13,401.07
  • 100 Day
  • ₹11,905.83
  • 200 Day
  • ₹9,815.98

Resistance and Support

15285.13 Pivot Speed
  • R3 18,526.12
  • R2 17,344.08
  • R1 16,467.17
  • S1 14,408.22
  • S2 13,226.18
  • S3 12,349.27

What's your outlook on Neuland Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system.

Neuland Laboratories has an operating revenue of Rs. 1,528.28 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 71% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-08-01 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.64%
4.04%
0.4%
26.46%
26.5%
9.96%

About Neuland Laboratories

  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹15,590 As on 17 November, 2024 | 06:40

The Market Cap of Neuland Laboratories is ₹20002.1 Cr As on 17 November, 2024 | 06:40

The P/E ratio of Neuland Laboratories is 71.5 As on 17 November, 2024 | 06:40

The PB ratio of Neuland Laboratories is 15.7 As on 17 November, 2024 | 06:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23